OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis $22.00 -0.01 (-0.02%) As of 08/9/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About H. Lundbeck A/S Stock (OTCMKTS:HLUYY) Get H. Lundbeck A/S alerts:Sign Up Key Stats Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/AConsensus RatingN/A Company Overview H. Lundbeck A/S (OTCMKTS:HLUYY) is a Danish pharmaceutical company headquartered in Copenhagen that specializes in the research, development and commercialization of medicines for disorders of the central nervous system. Founded in 1915 by Hans Lundbeck, the company has built a long-standing focus on neuroscience, concentrating on therapies for psychiatric and neurological conditions rather than broader therapeutic areas. Lundbeck’s primary activities include discovery and clinical development of novel compounds, regulatory filings, manufacturing and global commercialization of prescription medicines aimed at brain health. Its therapeutic portfolio and development programs address conditions such as major depressive disorder, anxiety, schizophrenia, Alzheimer’s disease, Parkinson’s disease and other neurological disorders. Among its better-known products are selective serotonin reuptake inhibitors and later-generation antidepressants as well as treatments for cognitive symptoms of Alzheimer’s disease; the company also maintains an active pipeline of investigational medicines and lifecycle projects in neuroscience. Operating across Europe, the Americas and the Asia‑Pacific region, Lundbeck conducts research in-house and through collaborations with academic institutions and industry partners, and pursues licensing and commercial partnerships to extend the reach of its products. The company’s strategic emphasis remains on advancing treatments that improve outcomes for patients with brain disorders while reinforcing its research capabilities in neuroscience and neurodegenerative disease.AI Generated. May Contain Errors. Read More Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLUYY Stock News HeadlinesAvadel board declares Lundbeck proposal superior to Alkermes offerNovember 17, 2025 | msn.comAvadel Pharmaceuticals plc Confirms Receipt of Unsolicited Acquisition Proposal from H. Lundbeck A/SNovember 14, 2025 | quiverquant.comQYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Lundbeck and Contera partner for oligonucleotide-based medicinesOctober 22, 2025 | msn.comH. Lundbeck A/S Cl BOctober 12, 2025 | barrons.comFDA Issues Complete Response Letter to Otsuka and Lundbeck for PTSD TreatmentSeptember 21, 2025 | tipranks.comH. Lundbeck A/S Advances Clinical Trial for Promising MSA TreatmentAugust 22, 2025 | tipranks.comH. Lundbeck A/S Advances Pediatric Migraine Treatment with Eptinezumab StudyAugust 14, 2025 | tipranks.comSee More Headlines HLUYY Stock Analysis - Frequently Asked Questions How have HLUYY shares performed this year? H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The firm earned $547.05 million during the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%. Does H. Lundbeck A/S have any subsidiaries? H. Lundbeck A/S subsidiaries include Alder BioPharmaceuticals, and Prexton Therapeutics. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2015Today5/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:HLUYY CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Trailing Twelve Months)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:HLUYY) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
